drugset / Trial / NCT00095758

A Study of Adjunctive Aripiprazole in Participants With Major Depressive Disorder

NCT00095758

RandomizedParallel-groupDouble-blindTreatment

Summary

This trial is a 14 week, randomized, double-blind, placebo controlled study, to assess the safety and efficacy of aripiprazole as adjunctive treatment to an ongoing antidepressant treatment in patients with Major Depressive Disorder.

Timeline

Start
2004-09-01
Primary completion
2006-12-01
Completion
2006-12-01

Publications

Drugs

EvaluationDrugModalityDoseRoute
Comparator Aripiprazole Other / unclassified 2 mg Oral
Comparator Aripiprazole Other / unclassified 20 mg Oral